Samsung BioLogics will open a research and development (R&D) center for the contract development organization (CDO) business in San Francisco, the United States, in April, the company announced at the JP Morgan Healthcare Conference in San Francisco on Jan. 15 (local time).
John Lim, vice president of Samsung BioLogics, said the company plans to increase the number of contract manufacturing organization (CMO) products to 47 this year from 27 in 2018 and 35 in 2019. This will boost the utilization of the company’s third plant from 35 percent to 60 percent or higher.
The plan does not include the productin of aducanumab, a treatment of Alzheimer's disease being developed by Biogen of the United States. Biogen has completed its phase 3 clinical trial of the new treatment and is waiting for approval by the U.S. Food and Drug Administration. If Biogen wins FDA approval on aducanumab, it is likely to outsource the new drug’s production to Samsung BioLogics. “If the FDA approves aducanumab, the third plant will reach its highest utilization rate,” Lim said.
He also said “If the CDO business supports the CMO business, Samsung BioLogics will have to build a new plant in 2022,” adding, “We are looking for a new site in Songdo.”